NCT02001974 - Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2012

Primary Completion Date

June 25, 2014

Study Completion Date

January 15, 2015

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Paclitaxel+Reparixin

Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin

Trial Locations (5)

Thomas Jefferson University Hospital; 1025 Walnut Street, Philadelphia

Fox Chase Cancer Center; 333 Cottman Avenue, Philadelphia

University of Kansas Medical Center; 4350 Shawnee Mission Parkway, Fairway

Pinnacle Oncology Hematology; 9055 East Del Camino, Scottsdale

University of Michigan; 1500 East Medical Center Drive, Ann Arbor